Author:
Kay Jonathan,Cross Raymond K.,Feldman Steven R.,Park Younjin,Hanauer Stephen B.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference39 articles.
1. FDA. Prescribing information—HUMIRA (Adalimumab). 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125057s417lbl.pdf. Accessed 30 Mar 2023.
2. FDA. Purple book—database of licensed biological products. 2023. https://purplebooksearch.fda.gov/. Accessed 30 Mar 2023.
3. FDA. What is a biosimilar? https://www.fda.gov/media/108905/download. Accessed 30 Mar 2023.
4. Norman P. Humira: the impending patent battles over adalimumab biosimilars. Pharm Pat Anal. 2016;5(3):141–5.
5. Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献